Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): STB-C017
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2020
Details:
Triple combination therapy of STB-C017, PD-1, CTLA-4 immune checkpoint inhibitors (ICIs) presented complete remission (CR) of tumor and long-term survival benefit.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): LCB73
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Iksuda
Deal Size: $227.0 million Upfront Cash: $5.0 million
Deal Type: Licensing Agreement May 15, 2020
Details:
LCB73 has been generated in a partnership between LCB and Swiss-based Light Chain Bioscience’s (Novimmune SA) by combining LCB’s cancer-selectively activated next-generation linker and toxin platform with Light Chain Bioscience’s proprietary antibody targeting CD19.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GEN-001,Avelumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2020
Details:
Clinical partnership of phase 1/1b combination clinical trial with Genome & Company's GEN-001, and avelumab, Merck KGaA, Darmstadt, Germany and Pfizer Inc.'s anti-PD-L1 antibody in cancer.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
